

CORRECTION

Open Access



Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

Giulio Cavalli^{1,2,3*}, Alessandro Tomelleri^{1,2}, Giacomo De Luca^{1,2}, Corrado Campochiaro¹, Charles A. Dinarello^{3,4}, Elena Baldissera¹ and Lorenzo Dagna^{1,2}

Correction to: *Arthritis Res Ther*

<https://doi.org/10.1186/s13075-019-1843-9>

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna's name. The authors apologise for the error.

Incorrect spelling:

Loreno Dagna

Correct spelling:

Lorenzo Dagna

The original article [1] has been updated.

Author details

¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy. ²Vita-Salute San Raffaele University, Milan, Italy. ³Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. ⁴Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.

Received: 19 February 2019 Accepted: 19 February 2019

Published online: 25 February 2019

Reference

1. Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. *Arthritis Res Ther*. 2019;21:54 <https://doi.org/10.1186/s13075-019-1843-9>.

* Correspondence: cavalli.giulio@gmail.com

¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy

²Vita-Salute San Raffaele University, Milan, Italy

Full list of author information is available at the end of the article

